{"organizations": [], "uuid": "c322471ac4d5382714aa5a19df0f63def1e115e4", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-abeona-receives-fda-regenerative-m/brief-abeona-receives-fda-regenerative-medicine-advanced-therapy-status-for-experimental-gene-therapy-for-rare-skin-disorder-idUSFWN1PO108", "country": "US", "domain_rank": 408, "title": "BRIEF-Abeona Receives FDA Regenerative Medicine Advanced Therapy Status For Experimental Gene Therapy For Rare Skin Disorder", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-29T15:50:00.000+02:00", "replies_count": 0, "uuid": "c322471ac4d5382714aa5a19df0f63def1e115e4"}, "author": "", "url": "https://www.reuters.com/article/brief-abeona-receives-fda-regenerative-m/brief-abeona-receives-fda-regenerative-medicine-advanced-therapy-status-for-experimental-gene-therapy-for-rare-skin-disorder-idUSFWN1PO108", "ord_in_thread": 0, "title": "BRIEF-Abeona Receives FDA Regenerative Medicine Advanced Therapy Status For Experimental Gene Therapy For Rare Skin Disorder", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda regenerative medicine advanced", "sentiment": "negative"}, {"name": "epidermolysis bullosa", "sentiment": "none"}, {"name": "fda", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "abeona therapeutics inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 29, 2018 / 1:51 PM / in 10 minutes BRIEF-Abeona Receives FDA Regenerative Medicine Advanced Therapy Status For Experimental Gene Therapy For Rare Skin Disorder Reuters Staff \nJan 29 (Reuters) - Abeona Therapeutics Inc: \n* ABEONA RECEIVES FDA REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR EB-101 GENE THERAPY IN EPIDERMOLYSIS BULLOSA \n* ABEONA THERAPEUTICS - CONTINUES TO ENGAGE FDA ON ITS PIVOTAL PHASE 3 CLINICAL TRIAL DESIGN, AND WILL PROVIDE AN UPDATE ON RMAT PROGRAM IN COMING MONTHS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-29T15:50:00.000+02:00", "crawled": "2018-01-29T16:11:05.018+02:00", "highlightTitle": ""}